In T-cells type-I IFNs induce STAT1 that is an inducer of TBX21 [53,54], which may explain the increased TBX21 expression levels we found in CD4+ T-cells from IFN-β treated MS patients. This evidence concerns the gene SGCG and myeloid sarcoma.